{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:04:28Z","timestamp":1773317068042,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jid.2021.04.036","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T05:38:51Z","timestamp":1628055531000},"page":"355-363.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1091-4733","authenticated-orcid":false,"given":"Stefano","family":"Piaserico","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-9001","authenticated-orcid":false,"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8161-6138","authenticated-orcid":false,"given":"Simone","family":"Cazzaniga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8668-2388","authenticated-orcid":false,"given":"Sara","family":"Di Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3160-2835","authenticated-orcid":false,"given":"Luigi","family":"Naldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2021.04.036_bib1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jaad.2020.10.046","article-title":"Incidence of severe COVID-19 outcomes in\u00a0psoriatic patients treated with systemic therapies during the pandemic: a Biobadaderm cohort analysis","volume":"84","author":"Baniandr\u00e9s-Rodr\u00edguez","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.04.036_bib2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jama.2020.11764","article-title":"Editorial evaluation and peer review during a pandemic: how journals maintain standards","volume":"324","author":"Bauchner","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jid.2021.04.036_bib3","doi-asserted-by":"crossref","first-page":"e14516","DOI":"10.1111\/dth.14516","article-title":"Does therapy with biological drugs influence COVID-19 infection? Observational monocentric prevalence study on the clinical and epidemiological data of psoriatic patients treated with biological drugs or with topical drugs alone","volume":"33","author":"Brazzelli","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2021.04.036_bib4","doi-asserted-by":"crossref","first-page":"105095","DOI":"10.1016\/j.jbspin.2020.105095","article-title":"COVID-19 in French patients with chronic inflammatory rheumatic diseases: clinical features, risk factors and treatment adherence","volume":"88","author":"Costantino","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jid.2021.04.036_bib5","doi-asserted-by":"crossref","first-page":"e13475","DOI":"10.1111\/dth.13475","article-title":"Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during red-zone declaration","volume":"33","author":"Damiani","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2021.04.036_bib6","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1111\/jdv.17025","article-title":"COVID-19 in patients with cutaneous immune-mediated diseases in The Netherlands: real-world observational data","volume":"35","author":"de Wijs","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2021.04.036_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ije\/dyp174","article-title":"How to assess the external validity of therapeutic trials: a conceptual approach","volume":"39","author":"Dekkers","year":"2010","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jid.2021.04.036_bib8","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/art.41388","article-title":"Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data?","volume":"72","author":"Favalli","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jid.2021.04.036_bib9","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(20)30858-8","article-title":"Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed","volume":"395","author":"Feldmann","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2021.04.036_bib10","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1007\/s10067-020-05334-7","article-title":"COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series","volume":"39","author":"Ferri","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jid.2021.04.036_bib11","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/ajg.2013.138","article-title":"Opportunistic infections with anti-tumor necrosis factor-\u03b1 therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials","volume":"108","author":"Ford","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jid.2021.04.036_bib12","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1111\/jdv.16761","article-title":"Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19","volume":"34","author":"Fougerousse","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2021.04.036_bib13","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1016\/S2665-9913(20)30169-7","article-title":"Brescia Rheumatology COVID-19 Study Group. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study","volume":"2","author":"Fredi","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jid.2021.04.036_bib14","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jaad.2020.07.021","article-title":"Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: a Canadian multicenter retrospective study","volume":"83","author":"Georgakopoulos","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.04.036_bib15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1177\/1203475420930226","article-title":"Rate of patient-driven biologic treatment discontinuation during the COVID-19 pandemic in 2 academic hospital clinics at the University of Toronto","volume":"24","author":"Georgakopoulos","year":"2020","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.jid.2021.04.036_bib16","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registryAnn","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2021.04.036_bib17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/bjd.19158","article-title":"The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience","volume":"183","author":"Gisondi","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.04.036_bib18","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jaci.2020.10.032","article-title":"Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: a Northern Italy","volume":"147","author":"Gisondi","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2021.04.036_bib19","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jaad.2020.04.085","article-title":"Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment","volume":"83","author":"Gisondi","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.04.036_bib20","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jclinepi.2013.03.003","article-title":"Testing the Newcastle Ottawa Scale showed low reliability between individual reviewers","volume":"66","author":"Hartling","year":"2013","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jid.2021.04.036_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001332","article-title":"National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD","volume":"6","author":"Hasseli","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.jid.2021.04.036_bib22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1471-2458-13-154","article-title":"Are healthcare workers' intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review","volume":"13","author":"Herzog","year":"2013","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jid.2021.04.036_bib23","doi-asserted-by":"crossref","first-page":"e776","DOI":"10.1111\/jdv.16867","article-title":"Severe COVID-19 outcomes in patients with psoriasis","volume":"34","author":"Lima","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2021.04.036_bib24","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.abc1731","article-title":"Against pandemic research exceptionalism","volume":"368","author":"London","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jid.2021.04.036_bib25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaci.2020.10.007","article-title":"Factors associated with adverse COVID-19 outcomes in patients with psoriasis\u2014insights from a global registry-based study","volume":"147","author":"Mahil","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2021.04.036_bib26","doi-asserted-by":"crossref","first-page":"e13707","DOI":"10.1111\/ijcp.13707","article-title":"Incidence and case fatality rate of COVID-19 in patients with inflammatory articular diseases","volume":"75","author":"Mena V\u00e1zquez","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jid.2021.04.036_bib27","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00296-020-04676-4","article-title":"Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes","volume":"40","author":"Montero","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jid.2021.04.036_bib28","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMc2018011","article-title":"More on Covid-19 in immune-mediated inflammatory diseases","volume":"383","author":"Naldi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.04.036_bib29","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1136\/annrheumdis-2020-218296","article-title":"Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study","volume":"79","author":"Pablos","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2021.04.036_bib30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41577-020-0328-z","article-title":"COVID-19: A case for inhibiting IL-17?","volume":"20","author":"Pacha","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2021.04.036_bib31","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s40257-020-00552-w","article-title":"Lack of evidence for an increased risk of severe COVID-19 in psoriasis patients on biologics: a\u00a0cohort study from Northeast Italy","volume":"21","author":"Piaserico","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jid.2021.04.036_bib32","first-page":"1","article-title":"The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies","author":"Pirro","year":"2020","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jid.2021.04.036_bib33","first-page":"1","article-title":"Patient\u00b4s perspective: psychological burden of the COVID-19 pandemic in 146 psoriatic patients treated with biological drugs and small molecules in real clinical practice","author":"Rodr\u00edguez-Villa Lario","year":"2020","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jid.2021.04.036_bib34","series-title":"Development of quality criteria to evaluate nontherapeutic studies of incidence, prevalence, or risk factors of chronic diseases: pilot study of new checklists","author":"Shamliyan","year":"2011"},{"key":"10.1016\/j.jid.2021.04.036_bib35","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jid.2021.04.036_bib36","unstructured":"Stefanini G. Effects of COVID-19 scientific pressure on quality of published evidence. Paper presented at: Virtual European Society of Cardiology Congress. 29 August\u201301 September 2020; Amsterdam, The Netherlands."},{"key":"10.1016\/j.jid.2021.04.036_bib37","doi-asserted-by":"crossref","first-page":"8642","DOI":"10.4081\/dr.2020.8642","article-title":"Psoriasis, biological drugs and coronavirus disease 2019: real life experience of two Italian provinces","volume":"12","author":"Vispi","year":"2020","journal-title":"Dermatol Reports"},{"key":"10.1016\/j.jid.2021.04.036_bib38","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jaad.2020.05.035","article-title":"The risk of respiratory tract infections\u00a0and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: a meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic","volume":"83","author":"Wan","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.04.036_bib39","author":"Wells"},{"key":"10.1016\/j.jid.2021.04.036_bib40","article-title":"Scientific quality of COVID-19 and SARS CoV-2 publications in the highest impact medical journals during the early phase of the pandemic: a case control study [published correction appears in PloS One 2021;16:e0250141]","volume":"15","author":"Zdravkovic","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2021.04.036_bib41","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jaad.2020.10.046","article-title":"Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: a Biobadaderm cohort analysis","volume":"84","author":"Baniandr\u00e9s-Rodr\u00edguez","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.04.036_bib42","doi-asserted-by":"crossref","first-page":"e14516","DOI":"10.1111\/dth.14516","article-title":"Does therapy with biological drugs influence COVID-19 infection? Observational monocentric prevalence study on the clinical and epidemiological data of psoriatic patients treated with biological drugs or with topical drugs alone","volume":"33","author":"Brazzelli","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2021.04.036_bib43","doi-asserted-by":"crossref","first-page":"105095","DOI":"10.1016\/j.jbspin.2020.105095","article-title":"COVID-19 in French patients with chronic inflammatory rheumatic diseases: clinical features, risk factors and treatment adherence","volume":"88","author":"Costantino","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jid.2021.04.036_bib44","doi-asserted-by":"crossref","first-page":"e13475","DOI":"10.1111\/dth.13475","article-title":"Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during red-zone declaration","volume":"33","author":"Damiani","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2021.04.036_bib45","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1111\/jdv.17025","article-title":"COVID-19 in patients with cutaneous immune-mediated diseases in The Netherlands: real-world observational data","volume":"35","author":"de Wijs","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2021.04.036_bib46","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/art.41388","article-title":"Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data?","volume":"72","author":"Favalli","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jid.2021.04.036_bib47","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1007\/s10067-020-05334-7","article-title":"COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series","volume":"39","author":"Ferri","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jid.2021.04.036_bib48","doi-asserted-by":"crossref","first-page":"e676","DOI":"10.1111\/jdv.16761","article-title":"Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19","volume":"34","author":"Fougerousse","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2021.04.036_bib49","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1016\/S2665-9913(20)30169-7","article-title":"COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study","volume":"2","author":"Fredi","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jid.2021.04.036_bib50","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jaad.2020.07.021","article-title":"Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: a Canadian multicenter retrospective study","volume":"83","author":"Georgakopoulos","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.04.036_bib51","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1177\/1203475420930226","article-title":"Rate of patient-driven biologic treatment discontinuation during the COVID-19 pandemic in 2 academic hospital clinics at the University of Toronto","volume":"24","author":"Georgakopoulos","year":"2020","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jid.2021.04.036_bib52","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registryAnn","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2021.04.036_bib53","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/bjd.19158","article-title":"The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience","volume":"183","author":"Gisondi","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.04.036_bib54","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jaci.2020.10.032","article-title":"Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: a Northern Italy","volume":"147","author":"Gisondi","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2021.04.036_bib55","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jaad.2020.04.085","article-title":"Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment","volume":"83","author":"Gisondi","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.04.036_bib56","doi-asserted-by":"crossref","first-page":"e001332","DOI":"10.1136\/rmdopen-2020-001332","article-title":"National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD","volume":"6","author":"Hasseli","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.jid.2021.04.036_bib57","doi-asserted-by":"crossref","first-page":"e776","DOI":"10.1111\/jdv.16867","article-title":"Severe COVID-19 outcomes in patients with psoriasis","volume":"34","author":"Lima","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2021.04.036_bib58","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaci.2020.10.007","article-title":"Factors associated with adverse COVID-19 outcomes in patients with psoriasis\u2014insights from a global registry-based study","volume":"147","author":"Mahil","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2021.04.036_bib59","doi-asserted-by":"crossref","first-page":"e13707","DOI":"10.1111\/ijcp.13707","article-title":"Incidence and case fatality rate of COVID-19 in patients with inflammatory articular diseases","volume":"75","author":"Mena V\u00e1zquez","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jid.2021.04.036_bib60","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00296-020-04676-4","article-title":"Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes","volume":"40","author":"Montero","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jid.2021.04.036_bib61","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1136\/annrheumdis-2020-218296","article-title":"Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study","volume":"79","author":"Pablos","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2021.04.036_bib62","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s40257-020-00552-w","article-title":"Lack of evidence for an\u00a0increased risk of severe COVID-19 in psoriasis patients on biologics: a\u00a0cohort study from Northeast Italy","volume":"21","author":"Piaserico","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jid.2021.04.036_bib63","first-page":"1","article-title":"The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies [e-pub ahead of print]","author":"Pirro","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jid.2021.04.036_bib64","first-page":"1","article-title":"Patient's perspective: psychological burden of the COVID-19 pandemic in 146 psoriatic patients treated with biological drugs and small molecules in real clinical practice [e-pub ahead of print]","author":"Rodr\u00edguez-Villa Lario","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jid.2021.04.036_bib65","doi-asserted-by":"crossref","first-page":"8642","DOI":"10.4081\/dr.2020.8642","article-title":"Psoriasis, biological drugs and coronavirus disease 2019: real life experience of two Italian provinces","volume":"12","author":"Vispi","year":"2020","journal-title":"Dermatol Reports"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21016547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21016547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:26:30Z","timestamp":1758302790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X21016547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0022202X21016547"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2021.04.036","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2021.04.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}